Heterotopic Gastric Mucosa in Cervical Oesophagus: Clinical Observations

Aim. Description of the endoscopic and clinical traits of heterotopic gastric mucosa (HGM) observed in cervical oesophagus.Key points. HGM in proximal oesophagus can be asymptomatic or have various clinical manifestations. A 40-yo female patient consulted a gastroenterologist with complaints of cough and globus sensation. For several years she was visiting an otorhinolaryngologist and psychotherapist, with therapy ineffective. Esophagogastroduodenoscopy (EGDS) at the last visit revealed several foci of HGM in cervical oesophagus of 1.2 x 0.8 cm maximal size. The patient was prescribed a combined prokinetic — proton pump inhibitor therapy, which relieved the symptoms. EGDS in a 21-yo patient without active complaints revealed a 2 cm-wide HGM of 4/5 cervical oesophageal lining with acidproducing zones.Conclusion. Two different scenarios of cervical oesophageal HGM are described, the first one manifested with laryngopharyngeal reflux, and the second devoid of clinical manifestations despite a large heterotopic site.

Download Full-text

A Systematic Review of Proton-Pump Inhibitor Therapy for Laryngopharyngeal Reflux

Ear Nose & Throat Journal ◽

10.1177/014556131309200811 ◽

2013 ◽

Vol 92 (8) ◽

pp. 364-371 ◽

Cited By ~ 4

Author(s):

Uchechukwu C. Megwalu

Keyword(s):

Systematic Review ◽

Proton Pump Inhibitor ◽

Proton Pump ◽

Laryngopharyngeal Reflux ◽

Proton Pump Inhibitor Therapy ◽

Inhibitor Therapy

Download Full-text

Effects of Proton Pump Inhibitor Therapy for Laryngopharyngeal Reflux on Posttreatment Symptoms and Hypopharyngeal pH

Otolaryngology ◽

10.1177/0194599814525577 ◽

2014 ◽

Vol 150 (6) ◽

pp. 1010-1017 ◽

Cited By ~ 5

Author(s):

Jonathan Waxman ◽

Sreeya Yalamanchali ◽

Elizabeth Shay Valle ◽

Thomas Pott ◽

Michael Friedman

Keyword(s):

Proton Pump Inhibitor ◽

Proton Pump ◽

Laryngopharyngeal Reflux ◽

Proton Pump Inhibitor Therapy ◽

Inhibitor Therapy

Download Full-text

A clinical study of symptomatic profile and response in objective and subjective parameters to proton pump inhibitor in laryngopharyngeal reflux

International Journal of Otorhinolaryngology and Head and Neck Surgery ◽

10.18203/issn.2454-5929.ijohns20163473 ◽

2016 ◽

Vol 2 (4) ◽

pp. 238

Author(s):

Kavitha Y. ◽

Angshuman Dutta ◽

Sabarigirish K. ◽

Joish Upendra Kumar

Keyword(s):

Proton Pump Inhibitor ◽

Proton Pump ◽

Laryngopharyngeal Reflux ◽

Proton Pump Inhibitor Therapy ◽

Common Finding ◽

Therapeutic Trial ◽

Dietary Recommendations ◽

Reflux Symptom Index ◽

Presumptive Diagnosis ◽

Symptom Index

Background: The study was conducted to identify the various clinical presentations and findings in cases of LPR and also to study the role of proton pump inhibitor in the management of laryngopharyngeal reflux by observing the effect of proton pump inhibitor on reflux finding score (RFI) and reflux symptom index (RSI).Methods: A prospective, interventional, cohort study of 50 diagnosed cases of LPR with RSI >13 and RFS >7 (based on fibreoptic laryngoscopic findings) at the time of initial presentation was done. They were treated with a 6 month course of oral cap omeprazole (20 mg twice daily 30 minutes before meals) and followed up at 0, 4, 8 and 24 weeks for any improvement in RSI and RFS scores. Results: Most frequent symptoms detected in the cases were frequent clearing of throat, dry cough and sensation of lump in the throat all of which showed significant improvement at follow up at 4 weeks. Most common finding on fibreoptic laryngoscopy was erythema and diffuse laryngeal oedema, both of which showed significant improvement on follow up.There was also a significant change in RSI and RFS after receiving Omeprazole at 4 weeks, 8 weeks and at 24 weeks duration (p <0.0001).Conclusions: This study dealt mainly with study of combination of clinical features that LPR presents time line of improvement of these features with capsule omeprazole. It is proposed that a presumptive diagnosis of LPR can be made based on the criteria of RSI and patients be given an empirical therapeutic trial including behavioral and dietary recommendations and 6 months of twice-daily proton-pump inhibitor therapy for an excellent clinical response.

Download Full-text